[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: ::
Back to the articles list Back to browse issues page
Radiotherapy-associated alterations in granulomatous mastitis: Clinicopathological and immunohistochemical predictors of recurrence and differential diagnosis from breast tumors
X. Zhao , J.Y. Li , C.W. Zhang , L.J. Ma , Y. Zhao , X.H. Chen , X.L. Li
epartment of Breast Surgery, The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei Province, China , lxlong201909@163.com
Abstract:   (14 Views)
Background: Granulomatous mastitis (GM) often recurs, and its clinical and pathological overlap with breast malignancies is especially problematic in patients with prior radiotherapy. To identify clinical, pathological, and immunohistochemical predictors of GM recurrence and to evaluate diagnostic challenges in the context of post-radiotherapy alterations. Materials and Methods: A retrospective cohort of 206 GM patients was analyzed (58 with recurrence, 148 without). Baseline clinical factors, pathological features, and immunohistochemical markers were compared. An XGBoost algorithm was applied to construct and validate a recurrence risk model. For patients with a history of breast radiotherapy, additional subgroup analysis was performed, incorporating imaging and pathology review to differentiate GM recurrence from tumor relapse. Results: Recurrence was associated with younger age (<35 years, 41.4% vs. 18.9%, P<0.001), higher prolactin levels (32.5±8.7 vs. 24.8±6.9 ng/mL, P<0.001), and higher BMI (26.4±3.8 vs. 24.1±3.2, P=0.007). Pathological indicators included multinucleated giant cells (31.0% vs. 12.2%, P<0.001), diffuse plasma cell infiltration (82.8% vs. 62.2%, P=0.003), and elevated Ki-67 (65.5% vs. 32.4%, P<0.001). The model achieved strong predictive performance (AUC = 0.89 training, 0.85 validation, 0.83 external). In post-radiotherapy patients, fibrotic distortion and atypical immune marker expression (Ki-67, PD-L1) frequently mimicked malignancy, highlighting the need for integrated clinicopathologic assessment. Conclusion: GM recurrence is driven by hormonal imbalance, immune dysregulation, and tissue injury. Radiotherapy-associated alterations exacerbate diagnostic overlap with breast tumors, underscoring the value of multidimensional prediction models for risk stratification and differential diagnosis.
Keywords: Granulomatous mastitis, breast neoplasms, recurrence, radiotherapy, immunohistochemistry, risk factors, predictive models.
Full-Text [PDF 898 kb]   (3 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Back to the articles list Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 50 queries by YEKTAWEB 4735